Mansilla E1, Rangel R2, Marín GH3, Zotarelli Filho I4, Rivas E5, Rivas J6, Carvalho KAT7, Dayer MR8 and Samadikuchaksaraei A9.
1.Eduardo Mansilla, MD.
Professor and Head Internal Medicine, School of Medical Sciences, UNLP, Argentina.
Correspondence Author.
E-mail: mansillaeduardo1@gmail.com
Tel: +5492214280275
2.Ricardo Rangel Martínez, BSB.
General Director ExomePharma, Ciudad de México DF, México.
3. Gustavo Horacio Marín, MD.
Professor of Pharmacology, School of Medical Sciences, UNLP,
Argentina.
4.Idiberto Zotarelli Filho, Ph.D.
Professor of Faceres Medical School, São José do Rio Preto, São Paulo, Brazil.
5.Elsa Rivas, MD.
Intensive Care Units-Hospital de la Amistad Perú Corea II, Santa Rosa and Salvador University Hospital, Piura, Perú.
6.Jaime Rivas, MD.
Intensive Care Unit, Hospital de la Amistad Perú Corea II, Santa Rosa, Piura, Perú.
7. Katherine Athayde Teixeira de Carvalho, MD, Ph.D.
Professor of Pequeno Príncipe Faculty & Pelé Pequeno Príncipe Institute Curitiba, Paraná, Brazil.
8.Mohammad Reza Dayer, Ph.D.
Associate Professor, Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
9. Alí Samadikuchaksaraei, MD, PhD.
Professor and Head Department of Tissue Engineering & Regenerative Medicine, Iran University of Medical Sciences, Tehran, Iran.